BioCentury
ARTICLE | Emerging Company Profile

Congruence: identifying protein folding correctors in silico

Montreal-based newco is cataloging properties of misfolded proteins and building a virtual chemical library to screen for stabilizers

March 8, 2022 10:36 PM UTC

Congruence is betting its computational platform can home in on the biophysical properties of misfolded proteins that drive rare diseases and identify pharmacological stabilizers capable of counteracting their effects.

Montreal-based Congruence Therapeutics Inc. emerged from stealth last month with a $50 million series A round, led by Amplitude Ventures and Fonds de solidarité FTQ, and CEO Clarissa Desjardins at the helm. Desjardins was CEO of rare disease play Clementia Pharmaceuticals Inc., which was acquired by Ipsen Group (Euronext:IPN; Pink:IPSEY) in 2019 for $1 billion up front...